Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) and Grifols, (NASDAQ:GRFS) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, earnings, risk, profitability and valuation.
This is a breakdown of recent recommendations and price targets for Jazz Pharmaceuticals PLC and Grifols,, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Jazz Pharmaceuticals PLC||0||5||16||0||2.76|
Jazz Pharmaceuticals PLC presently has a consensus target price of $181.71, indicating a potential upside of 33.15%. Given Jazz Pharmaceuticals PLC’s stronger consensus rating and higher possible upside, equities analysts plainly believe Jazz Pharmaceuticals PLC is more favorable than Grifols,.
This table compares Jazz Pharmaceuticals PLC and Grifols,’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Jazz Pharmaceuticals PLC||23.58%||22.92%||10.07%|
Grifols, pays an annual dividend of $0.28 per share and has a dividend yield of 1.2%. Jazz Pharmaceuticals PLC does not pay a dividend. Grifols, pays out 30.1% of its earnings in the form of a dividend.
Risk & Volatility
Jazz Pharmaceuticals PLC has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.Comparatively, Grifols, has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500.
Institutional & Insider Ownership
88.9% of Jazz Pharmaceuticals PLC shares are owned by institutional investors. Comparatively, 21.8% of Grifols, shares are owned by institutional investors. 4.3% of Jazz Pharmaceuticals PLC shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares Jazz Pharmaceuticals PLC and Grifols,’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Jazz Pharmaceuticals PLC||$1.49 billion||5.50||$396.83 million||$6.07||22.48|
|Grifols,||$4.48 billion||3.47||$603.60 million||$0.93||24.52|
Grifols, has higher revenue and earnings than Jazz Pharmaceuticals PLC. Jazz Pharmaceuticals PLC is trading at a lower price-to-earnings ratio than Grifols,, indicating that it is currently the more affordable of the two stocks.
Jazz Pharmaceuticals PLC beats Grifols, on 11 of the 16 factors compared between the two stocks.
About Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder. Its marketed products and late-stage product candidate are Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) Extended-Release Capsules and JZP-6 (sodium oxybate). Its other product candidates in clinical development are oral tablet forms of sodium oxybate; JZP-8 (intranasal clonazepam); JZP-4 (elpetrigine), and JZP-7 (ropinirole gel).
Grifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics. It operates through four segments: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. This segment offers plasma products, such as IVIG, Factor VIII, A1PI, and albumin; and intramuscular immunoglobulins, ATIII, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products comprising analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. This segment serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment manufactures and installs products used by hospitals consisting of parenteral solutions, and enteral and parenteral nutritional fluids. The Raw Materials and Others segment sells intermediate biological products; and renders manufacturing services to third party companies. The company also offers engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.
Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.